PDMR Dealing / Grant of Share Options

RNS Number : 8887B

Oxford BioDynamics PLC

12 June 2019

 

12 June 2019

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

PDMR Dealing / Grant of Share Options

Oxford BioDynamics Plc (AIM: OBD) (the "Company"), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture for use within the pharmaceutical and biotechnology industry, announces that it has today granted a total of 190,000 options over its ordinary shares of 1 pence each, to certain Group employees and consultants, including 40,000 options to each of Dr David Holbrook and Dr Peter Pack, Non-Executive Directors of the Company. The options were granted under the Company's 2016 Employee and Non-Employee Share Option Plans with an exercise price of 158 pence per share.

One-third of the options granted will vest and become exercisable on the first anniversary of the grant date; one-third on the second anniversary and one-third on the third anniversary. Vested options will remain exercisable up to and including the tenth anniversary of the date of grant.

Following this grant, David Holbrook holds 40,000 options and Peter Pack holds 40,000 options. The notifications below, which are made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	David Holbrook
2	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oxford BioDynamics Plc
b)	LEI	2138005Y1TK258O5U928
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 1 pence each ISIN:   GB00BD5H8572
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	40,000 ordinary shares at an exercise price of 158 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	12 June 2019
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Peter Pack
2	Reason for the notification
a)	Position/status	Director/PDMR
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oxford BioDynamics Plc
b)	LEI	2138005Y1TK258O5U928
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 1 pence each ISIN:   GB00BD5H8572
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	40,000 ordinary shares at an exercise price of 158 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	12 June 2019
f)	Place of the transaction	Outside a trading venue

For further details please contact:

Oxford BioDynamics Plc Christian Hoyer Millar, CEO Paul Stockdale, CFO	[phone]
Shore Capital Nominated Adviser and Broker Stephane Auton Edward Mansfield	[phone]
FTI Consulting Financial Public Relations Adviser Brett Pollard Natalie Garland-Collins	[phone]

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

 

END

 

 

DSHFFLLFKQFEBBF